TrialSignal
Clinical trial intelligence report
Study of CAR-T Cells Targeting BCMA for Previously CAR-T Treated Refractory/Relapsed Multiple Myeloma
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT03672253-Jul 28, 2026
NCT ID
NCT03672253
Status
UNKNOWN
Phase
PHASE1
Sponsor
Second Affiliated Hospital of Xi'an Jiaotong University
Executive brief
Investment-Ready Snapshot
Study of CAR-T Cells Targeting BCMA for Previously CAR-T Treated Refractory/Relapsed Multiple Myeloma is a PHASE1 clinical asset sponsored by Second Affiliated Hospital of Xi'an Jiaotong University in Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma Progression. SEO and diligence focus: CAR-T Re-treatment, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03672253
Indication
Multiple Myeloma
Modality
cell therapy
Target
CAR-T Re-treatment
Intervention
CAR-T Re-treatment
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.